These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 617788)

  • 1. Characteristics and thrombogenicity of factor IX concentrate.
    Sakuragawa N; Takahashi K; Itoh M; Matsuoka M
    Bibl Haematol; 1977; 44():88-93. PubMed ID: 617788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thrombin generation is not increased in the blood of hemophilia B patients after the infusion of a purified factor IX concentrate.
    Mannucci PM; Bauer KA; Gringeri A; Barzegar S; Bottasso B; Simoni L; Rosenberg RD
    Blood; 1990 Dec; 76(12):2540-5. PubMed ID: 2265248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Importance of PPSB fraction in the treatment of hemophilia A with antibodies against factor VIII].
    Hrubisková K
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1980; 107(4):672-82. PubMed ID: 6162735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coagulation Factor IX concentrate: method of preparation and assessment of potential in vivo thrombogenicity in animal models.
    Menache D; Behre HE; Orthner CL; Nunez H; Anderson HD; Triantaphyllopoulos DC; Kosow DP
    Blood; 1984 Dec; 64(6):1220-7. PubMed ID: 6498336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. No activation of the common pathway of the coagulation cascade after a highly purified factor IX concentrate.
    Mannucci PM; Bauer KA; Gringeri A; Barzegar S; Santagostino E; Tradati FC; Rosenberg RD
    Br J Haematol; 1991 Dec; 79(4):606-11. PubMed ID: 1772782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resistance to activated F IX concentrate (FEIBA).
    Stenbjerg S; Jorgensen J
    Scand J Haematol; 1977 May; 18(5):421-6. PubMed ID: 877518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human coagulation factor IX: assessment of thrombogenicity in animal models and viral safety.
    Herring SW; Abildgaard C; Shitanishi KT; Harrison J; Gendler S; Heldebrant CM
    J Lab Clin Med; 1993 Mar; 121(3):394-405. PubMed ID: 8445288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
    CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A cross-over pharmacokinetic and thrombogenicity study of a prothrombin complex concentrate and a purified factor IX concentrate.
    Thomas DP; Hampton KK; Dasani H; Lee CA; Giangrande PL; Harman C; Lee ML; Preston FE
    Br J Haematol; 1994 Aug; 87(4):782-8. PubMed ID: 7986719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel therapeutic approach combining human plasma-derived Factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa alone.
    Tomokiyo K; Nakatomi Y; Araki T; Teshima K; Nakano H; Nakagaki T; Miyamoto S; Funatsu A; Iwanaga S
    Vox Sang; 2003 Nov; 85(4):290-9. PubMed ID: 14633255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disseminated intravascular coagulation and hemorrhage in hemophilia B following elective surgery.
    Conlan MG; Hoots WK
    Am J Hematol; 1990 Nov; 35(3):203-7. PubMed ID: 2220765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative efficacy of nonheated and heat-treated factor IX complex concentrate in treatment of hemophiliacs with inhibitors.
    Schwartz RS; Ewing NP; Gorenc TJ; Spero JA
    Am J Hematol; 1989 Jan; 30(1):22-6. PubMed ID: 2491929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hemophilia as a defect of the tissue factor pathway of blood coagulation: effect of factors VIII and IX on factor X activation in a continuous-flow reactor.
    Repke D; Gemmell CH; Guha A; Turitto VT; Broze GJ; Nemerson Y
    Proc Natl Acad Sci U S A; 1990 Oct; 87(19):7623-7. PubMed ID: 2120704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced coagulation activation following infusion of a highly purified factor IX concentrate compared to a prothrombin complex concentrate.
    Hampton KK; Preston FE; Lowe GD; Walker ID; Sampson B
    Br J Haematol; 1993 Jun; 84(2):279-84. PubMed ID: 8398831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Studies of factor IX concentrate therapy in hemophilia.
    Hultin MB
    Blood; 1983 Sep; 62(3):677-84. PubMed ID: 6603880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Properties of a highly purified human plasma factor IX:c therapeutic concentrate prepared by conventional chromatography.
    Burnouf T; Michalski C; Goudemand M; Huart JJ
    Vox Sang; 1989; 57(4):225-32. PubMed ID: 2617959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical experience of a new monoclonal antibody purified factor IX: half-life, recovery, and safety in patients with hemophilia B.
    Kim HC; McMillan CW; White GC; Bergman GE; Saidi P
    Semin Hematol; 1990 Apr; 27(2 Suppl 2):30-5. PubMed ID: 2094957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An alternative extrinsic pathway of human blood coagulation.
    Marlar RA; Kleiss AJ; Griffin JH
    Blood; 1982 Dec; 60(6):1353-8. PubMed ID: 7139124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contact activation and factor VII after the use of an activated prothrombin complex concentrate (FEIBA) in hemophiliacs with inhibitors.
    Mariani G; Bouma BN; Mazzucconi MG; Avvisati G; Di Nucci GD; Corrao D; Mandelli F
    Thromb Res; 1983 Aug; 31(3):475-88. PubMed ID: 20218003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the behavior of normal factor IX and the factor IX Bm variant Hilo in the prothrombin time test using tissue factors from bovine, human, and rabbit sources.
    Lefkowitz JB; Monroe DM; Kasper CK; Roberts HR
    Am J Hematol; 1993 Jul; 43(3):177-82. PubMed ID: 8352232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.